Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 271

1.
3.

The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes.

Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI.

Diabetes Care. 2005 Sep;28(9):2261-6.

PMID:
16123505
4.

Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes.

Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME.

J Hypertens. 2005 Mar;23(3):463-73. Review.

PMID:
15716683
5.
6.

Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension.

Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN.

Ann Intern Med. 2008 Jan 1;148(1):16-29. Epub 2007 Nov 5. Review.

PMID:
17984484
7.

Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.

Epstein BJ, Gums JG.

Ann Pharmacother. 2005 Mar;39(3):470-80. Epub 2005 Feb 8. Review.

PMID:
15701766
8.

Strategies to prevent type 2 diabetes.

Abuissa H, Bel DS, O'keefe JH Jr.

Curr Med Res Opin. 2005 Jul;21(7):1107-14. Review.

PMID:
16004680
9.

The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.

Kuti EL, Baker WL, White CM.

Curr Med Res Opin. 2007 Jun;23(6):1239-44. Epub 2007 Apr 23.

PMID:
17559720
10.
11.
13.

Pharmacologic management of diabetic nephropathy.

Vivian EM, Rubinstein GB.

Clin Ther. 2002 Nov;24(11):1741-56; discussion 1719. Review.

PMID:
12501871
14.

Metabolic syndrome: treatment of hypertensive patients.

Israili ZH, Lyoussi B, Hernández-Hernández R, Velasco M.

Am J Ther. 2007 Jul-Aug;14(4):386-402. Review.

PMID:
17667215
15.

Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.

Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J.

Am J Kidney Dis. 2005 Dec;46(6):1080-7.

PMID:
16310574
17.

Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis.

Al-Mallah M, Khawaja O, Sinno M, Alzohaili O, Samra AB.

Cardiol J. 2010;17(5):448-56.

18.

Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.

Volpe M, Tocci G, Sciarretta S, Verdecchia P, Trimarco B, Mancia G.

J Hypertens. 2009 May;27(5):941-6. doi: 10.1097/HJH.0b013e32832961ed.

PMID:
19381108
20.

Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.

Al Khalaf MM, Thalib L, Doi SA.

Am J Cardiovasc Drugs. 2009;9(1):29-43. doi: 10.2165/00129784-200909010-00004. Review.

PMID:
19178130

Supplemental Content

Support Center